153 related articles for article (PubMed ID: 16683014)
1. Evidence of a novel biomarker, alphas1-Casein, a milk protein, in benign prostate hyperplasia.
Xu K; Ling MT; Wang X; Wong YC
Prostate Cancer Prostatic Dis; 2006; 9(3):293-7. PubMed ID: 16683014
[TBL] [Abstract][Full Text] [Related]
2. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
3. Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma.
Alaiya AA; Al-Mohanna M; Aslam M; Shinwari Z; Al-Mansouri L; Al-Rodayan M; Al-Eid M; Ahmad I; Hanash K; Tulbah A; Bin Mahfooz A; Adra C
Int J Oncol; 2011 Apr; 38(4):1047-57. PubMed ID: 21305254
[TBL] [Abstract][Full Text] [Related]
4. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
5. Immunoreactivity of ubiquitin in human prostate gland.
Bataineh ZM; Habbal O
Neuro Endocrinol Lett; 2006 Aug; 27(4):517-22. PubMed ID: 16892003
[TBL] [Abstract][Full Text] [Related]
6. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
Abdou AG; Aiad HA; Sultan SM
APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
[TBL] [Abstract][Full Text] [Related]
7. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
8. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
[TBL] [Abstract][Full Text] [Related]
9. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
10. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.
Lee LM; Pan CC; Cheng CJ; Chi CW; Liu TY
Anticancer Res; 2001; 21(2B):1291-4. PubMed ID: 11396201
[TBL] [Abstract][Full Text] [Related]
11. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
12. Identification of a specifically expressed modified form of novel PSP-94 protein in the secretion of benign prostatic hyperplasia.
Xu K; Wang X; Ling MT; Lee DT; Fan T; Chan FL; Xuan JJ; Tsao SW; Wong YC
Electrophoresis; 2003 Apr; 24(7-8):1311-8. PubMed ID: 12707925
[TBL] [Abstract][Full Text] [Related]
13. [Expression and significance of PCNA and p27 in benign prostate hypertrophy and prostate carcinoma].
Lai JS; Xia Q; Zhang XB; Zhao GP; Xu SL; Zheng DS
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):476-8. PubMed ID: 15555337
[TBL] [Abstract][Full Text] [Related]
14. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
[TBL] [Abstract][Full Text] [Related]
15. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
16. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of NKX3.1 in benign prostatic hyperplasia.
Irer B; Toylu A; Aslan G; Celebi I; Yorukoglu K; Atabey N
Urology; 2009 May; 73(5):1140-4. PubMed ID: 18597829
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate.
Dema A; Tudose N
Rom J Morphol Embryol; 1998; 44(1-4):93-100. PubMed ID: 15678849
[TBL] [Abstract][Full Text] [Related]
19. Changes in keratin expression during the development of benign prostatic hyperplasia.
Xue Y; Smedts F; Umbas R; Aalders TW; Debruyne FM; de la Rosette JJ; Schalken JA
Eur Urol; 1997; 32(3):332-8. PubMed ID: 9358223
[TBL] [Abstract][Full Text] [Related]
20. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
